Alveolar Bone Loss, Alveolar Ridge Augmentation, Dental Implant
Conditions
Keywords
CGF, autogenous bone graft, gingival biotype, dental implant, guided tissue regeneration
Brief summary
CGF membranes will be prepared using a swing-lock centrifuge. A full-thickness mucoperiosteal flap will be elevated in a narrow alveolar ridge. Implants will be inserted. Autologous bone chips will be harvested via bone scraping and used for augmentation, CGF membranes will be placed over the grafted area. Suturing of the mucoperiosteal flap. Radiographic evaluation of the bone density and tissue thickness will be performed by CBCT preoperatively, immediate postoperative and after the procedure by 4 months. Clinical evaluation of the tissue thickness using periodontal probe preoperatively, immediate postoperatively and after the procedure by 4 months
Detailed description
* Preoperative cone-beam computed tomography (CBCT) images will be obtained for surgical planning and for later comparison during follow-up evaluations. * Clinical evaluation of the tissue thickness using periodontal probe * Signed consent from the patient agreeing to the procedure * All surgical procedures will be performed by the same oral surgeon, following a standardized protocol to ensure consistency. The surgeries will be conducted in a sterilized dental operatory prepared specifically for oral surgery. * Patient preparation will include preoperative instructions and aseptic measures. Sterile drapes will be placed to minimize contamination. * The patient will be prepared for phlebotomy, and a blood sample will be drawn into a sterile 10 mL tube without anticoagulant. The sample will be immediately centrifuged using a CGF-specific centrifuge under the designated CGF settings. To ensure proper balance during centrifugation, each tube will be counterbalanced with another tube containing either blood or water. After centrifugation is complete, the tubes will be removed, and the CGF clot will be carefully extracted. Using a PRF preparation tray, the red blood cell (RBC) layer will be separated from the fibrin matrix. The remaining CGF membrane will be ready for use. * Prior to surgery, the patient will rinse with 0.12% chlorhexidine gluconate as an antiseptic mouthwash. A topical anesthetic gel will be applied to the injection site prior to the administration of local anesthesia. Once both subjective and objective signs of anesthesia are confirmed, a mucoperiosteal flap will be elevated in a narrow alveolar ridge. * Autologous bone chips will be harvested via bone scraping and used for augmentation. * Implants will be inserted. * CGF membranes will be placed over the grafted area. * Interrupted sutures will be performed. Radiographic evaluation of the bone density and tissue thickness will be performed by CBCT, immediate postoperative and after the procedure by 4 months. Clinical evaluation of the tissue thickness using periodontal probe immediate postoperatively and after the procedure by 4 months.
Interventions
OTHERconcentrated growth factor (CGF) Membrane
This is a third-generation autologous blood concentrate prepared using a dedicated centrifuge system. The process creates a fibrin-rich organic matrix from the patient's own blood, which is then molded into a membrane and packed over the grafted bone to enhance bone density increase and improvement of the surrounding tissue.
Sponsors
Cairo University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A medical history that contraindicates oral surgical treatment such as (uncontrolled/untreated diabetes mellitus, immuno-compromised status, radio or chemotherapy of the oral and maxillofacial region, treatment with oral and/or intravenous bisphosphonates). * Presence of active or untreated periodontal disease. * Vertical root fractures involving the buccal aspect. * Tooth /teeth with horizontal fractures below bone level. * Tooth /teeth with external or internal resorption. * Patients with destructive oral habits such as smoking, chewing tobacco, bruxism,etcetera(Chrcanovic et al., 2014).
Exclusion criteria
A medical history that contraindicates oral surgical treatment such as (uncontrolled/untreated diabetes mellitus, immuno-compromised status, radio or chemotherapy of the oral and maxillofacial region, treatment with oral and/or intravenous bisphosphonates). * Presence of active or untreated periodontal disease. * Vertical root fractures involving the buccal aspect. * Tooth /teeth with horizontal fractures below bone level. * Tooth /teeth with external or internal resorption. * Patients with destructive oral habits such as smoking, chewing tobacco, bruxism, etcetera(Chrcanovic et al., 2014).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tissue biotype | preoperative, immediate postoperative and 4 months after the procedure | using periodontal probe to measure gingival thickness |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| bone density | preoperative, immediately postoperative, and 4 months after the surgery | cbct xray |
| patient satisfaction | after 4 months from the surgery | psq18 is a chart where the patient describes the level of their satisfaction |
Countries
Egypt
Contacts
CONTACTmeis youssef moustafa, bachelors
STUDY_CHAIRHesham Elsayed Elhawary, Professor
Cairo University
STUDY_DIRECTORAbdelmoez Mohamed El-Sharkawy, Assistant Professor
Cairo University
Outcome results
None listed